Use of Untested 'Wolverine' Peptide BPC-157 Surges Despite Limited Human Evidence, Study Finds

An analysis of clinical notes and medical records shows rising real-world use of the experimental peptide BPC-157—often combined with TB-500 in the so-called "Wolverine stack"—despite minimal human safety and efficacy data and no U.S. approval.

Background

BPC-157 is marketed online for pain relief, healing and performance enhancement but lacks a National Drug Code (NDC) and has not been approved by the U.S. Food and Drug Administration (FDA). The compound has gained traction in a gray market, amplified by social media claims of benefits for muscle growth and faster injury recovery that are not supported by rigorous human trials.

Regulatory Update

In July, an FDA advisory panel voted to permit pharmacy compounding of BPC-157—a shift from earlier FDA restrictions that cited safety concerns and insufficient human data. The vote followed public advocacy by U.S. Health Secretary Robert F. Kennedy Jr.

What the Study Found

Data analytics firm nference reviewed more than 15 million medical records and identified 1,039 patients whose clinicians manually documented BPC-157 use in written notes. Study leader Venky Soundararajan said the findings likely undercount total use, noting many clinicians probably do not ask patients whether they are taking the peptide.

The researchers reported a 33-fold increase in newly confirmed BPC-157 users between 2020 and 2026. Reasons for use were recorded for 644 patients and included sports injuries, chronic pain and gastrointestinal disorders. BPC-157 was most frequently initiated for pain management or gastrointestinal symptoms and was commonly obtained from compounding pharmacies or gray-market peptide vendors.

Who Is Using It?

The study found shifting demographics: the share of new users who were male rose from 57% in 2020 to 70% in 2026, and the average age dropped from 55 to 49. Among 972 users with recorded race, 96% were white.

Safety, Outcomes, And Limitations

Responses to treatment were documented for only about one-third of patients. While some clinical notes described symptom improvement, documentation was inconsistent. When patients discontinued BPC-157, the most commonly recorded reason was medical advice to stop; others cited adverse events including neuropsychiatric, dermatologic and gastrointestinal symptoms.

Dr. Flynn McGuire of the University of Utah, who has researched BPC-157 but was not involved in the analysis, emphasized major limitations: many patients were taking other therapies (testosterone, NSAIDs, TB-500, corticosteroids) or undergoing interventions such as physical therapy or surgery, and there was no placebo or untreated comparator, no standardized formulation or dosing, and no consistent outcome assessment.

"It is therefore impossible to know how much of any reported improvement was attributable to BPC-157 versus natural recovery, other treatments, placebo effects, or selective documentation," the authors wrote.

Market Potential And Next Steps

Analysts estimate that peptides like BPC-157 could become a $2 billion–$3 billion market if legitimized. Experts stress that randomized controlled trials are needed to determine whether BPC-157 provides clinically meaningful benefits and to clarify its safety profile.

Bottom Line

BPC-157 use is increasing in real-world settings, but evidence from controlled human studies remains sparse. Clinicians and patients should exercise caution and prioritize well-designed trials to guide safe and effective use.